The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 March 2026•

1 min read

Persistent Systems Partners with NVIDIA to Accelerate AI-Driven Drug Discovery

Key Facts

1Persistent Systems launched an AI-powered generative molecules and virtual screening solution.

2The new solution is developed in collaboration with NVIDIA.

Persistent Systems has announced the launch of a new generative molecules and virtual screening solution powered by artificial intelligence. Developed in collaboration with NVIDIA, the solution leverages advanced technology stacks to transform the life sciences landscape. The project aims to significantly accelerate digital engineering processes and drug discovery through the strategic application of generative AI. By integrating NVIDIA's specialized AI hardware and software, Persistent Systems provides researchers with faster and more efficient molecular screening tools. This strategic move is expected to strengthen the company's position in the high-growth digital engineering and healthcare sectors. Investors view this partnership as a positive development that underscores Persistent Systems' commitment to innovation in the AI domain.